$SNWV: NEWS JUST OUT---SANUWAVE Signs Distribution
Post# of 103059
(Total Views: 242)
Posted On: 11/13/2019 9:09:05 AM
$SNWV: NEWS JUST OUT---SANUWAVE Signs Distribution Partnership With Ametus Group, Setting Stage for Rapid Expansion in 2020
Press Release | 11/13/2019
Re-Affirms Guidance of 110 dermaPACE® Placements in 2019
SUWANEE, GA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that it has signed a distribution partnership agreement with Ametus Group for the commercialization of the dermaPACE® System for the treatment of diabetic foot ulcers in the United States. Leveraging Ametus Group’s fifty dedicated wound care sales force allows SANUWAVE to ramp up placements much faster than previously expected in a cost effective and capital efficient manner.
“Ametus Group leadership, along with our experienced and clinically consultative sales organization, are excited to partner with SANWUAVE to launch and drive market adoption of the cutting edge and unique PACE® technology utilized in dermaPACE®. We are very motivated by the positive clinical impact dermaPACE will have on thousands of diabetic patients with chronic foot ulcers,” stated Ametus Group co-founders and Managing Partners Randy Seeliger and Mark Will.
“Our partnership with SANUWAVE and the dermaPACE® System are highly accretive with other innovative advanced wound care product offerings Ametus Group currently sells,” added Randy Seeliger and Mark Will.
“The relationship with Ametus Group will allow SANUWAVE to enter markets more efficiently and on a cost-effective basis in 2020 and beyond. We chose Ametus Group based on their vast wound care experience backgrounds, and most importantly previous success,” stated Kevin Richardson, CEO and Chairman of SANUWAVE. “Ametus Group brings 50 wound care sales representatives to help train and sell dermaPACE Systems. The initial roll out is currently underway and covers Minnesota, Wisconsin, and Illinois. These are territories where NGS operates as a MAC, managing Medicare accounts. As we roll through in 2020, we will add mostly western states to the Ametus mix,” concluded Mr. Richardson.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shockwave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact:
Millennium Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE Health, Inc.
Kevin Richardson II
CEO and Chairman of the Board
978-922-2447
investorrelations@sanuwave.com
https://www.otcmarkets.com/stock/SNWV/news/SA...?id=246092
Press Release | 11/13/2019
Re-Affirms Guidance of 110 dermaPACE® Placements in 2019
SUWANEE, GA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that it has signed a distribution partnership agreement with Ametus Group for the commercialization of the dermaPACE® System for the treatment of diabetic foot ulcers in the United States. Leveraging Ametus Group’s fifty dedicated wound care sales force allows SANUWAVE to ramp up placements much faster than previously expected in a cost effective and capital efficient manner.
“Ametus Group leadership, along with our experienced and clinically consultative sales organization, are excited to partner with SANWUAVE to launch and drive market adoption of the cutting edge and unique PACE® technology utilized in dermaPACE®. We are very motivated by the positive clinical impact dermaPACE will have on thousands of diabetic patients with chronic foot ulcers,” stated Ametus Group co-founders and Managing Partners Randy Seeliger and Mark Will.
“Our partnership with SANUWAVE and the dermaPACE® System are highly accretive with other innovative advanced wound care product offerings Ametus Group currently sells,” added Randy Seeliger and Mark Will.
“The relationship with Ametus Group will allow SANUWAVE to enter markets more efficiently and on a cost-effective basis in 2020 and beyond. We chose Ametus Group based on their vast wound care experience backgrounds, and most importantly previous success,” stated Kevin Richardson, CEO and Chairman of SANUWAVE. “Ametus Group brings 50 wound care sales representatives to help train and sell dermaPACE Systems. The initial roll out is currently underway and covers Minnesota, Wisconsin, and Illinois. These are territories where NGS operates as a MAC, managing Medicare accounts. As we roll through in 2020, we will add mostly western states to the Ametus mix,” concluded Mr. Richardson.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shockwave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact:
Millennium Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE Health, Inc.
Kevin Richardson II
CEO and Chairman of the Board
978-922-2447
investorrelations@sanuwave.com
https://www.otcmarkets.com/stock/SNWV/news/SA...?id=246092
(0)
(0)
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.
Scroll down for more posts ▼